Table 2.
Response to Bortezomib Retreatment in Patients with Relapsed Myeloma
| Best confirmed responsea | Patients achieving response, N (N = 130) |
|---|---|
| Partial response or better | 50b |
| • Complete response | 1 |
| • Partial response | 49 |
| Overall response rate, % | 38.5 (95% CI, 30.1–47.4) |
a
As assessed by the European Group for Blood and Marrow Transplantation criteria.
b
In the 50 patients who responded, the median duration of response was 6.5 months (range, 0.6–19.3 months).
CI indicates confidence interval.
Source: Velcade (bortezomib) for injection prescribing information; October 2014.